TO-O-1001 ophthalmology solution
Category: Analytical/Test
Developers: Industrial Technology Research Institute (ITRI)
Co-Developers: TheratOcular Biotek Co., Ltd.
Taiwan
Product Description:TO-O-1001 is a novel ROCK and MYLK-4 dual-target medication. It shows promise for reducing trabecular meshwork blockage, enhancing aqueous humor outflow, and preserving the optic nerve. The TO-O-1001 eye drops offer safe and convenient treatment in glaucoma disease, highlighting its potential as a novel therapy.
Developers: Industrial Technology Research Institute (ITRI)
Co-Developers: TheratOcular Biotek Co., Ltd.
Taiwan
Product Description:TO-O-1001 is a novel ROCK and MYLK-4 dual-target medication. It shows promise for reducing trabecular meshwork blockage, enhancing aqueous humor outflow, and preserving the optic nerve. The TO-O-1001 eye drops offer safe and convenient treatment in glaucoma disease, highlighting its potential as a novel therapy.
Photo